Drug Research

SCIE

国际简称：DRUG RES 参考译名：药物研究

主要研究方向：PHARMACOLOGY & PHARMACY 非预警期刊

《药物研究》(Drug Research)是一本由Thieme出版的以PHARMACOLOGY & PHARMACY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
39 年发文量
2.4 IF影响因子
未开放 是否OA
12 issues/year 出版周期
Multi-Language 出版语言

Drug Research is an academic journal dedicated to drug research, managed by a professional team of scientific editors, aimed at providing a platform for global drug researchers to exchange and share the latest research findings. This magazine covers various aspects of drug research, including the discovery of new drugs, drug design and synthesis, drug mechanisms of action, clinical research of drugs, and evaluation of drug safety and efficacy. The main goal of the magazine is to promote the development of drug research, improve the level of drug research, and promote innovation in drug research. The readership of the magazine mainly includes drug researchers, clinical doctors, pharmacists, drug policy makers, and professionals in the pharmaceutical industry. By reading this magazine, these readers can obtain the latest drug research results, learn about the latest developments in drug research, and thus improve their professional competence and work efficiency.

[ 查看全部 ]

投稿咨询加急咨询

Drug Research期刊信息

ISSN：2194-9379
出版语言：Multi-Language
是否OA：未开放
E-ISSN：2194-9387
出版地区：GERMANY
是否预警：否
出版商：Thieme
出版周期：12 issues/year
开源占比：0.0139
Gold OA文章占比：1.52%
OA被引用占比：0.0023...
出版国人文章占比：0.04
出版撤稿占比：
研究类文章占比：76.92%

Drug Research CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

4.6

0.479

0.532

学科类别	分区	排名	百分位
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Drug Discovery	Q3	86 / 161	46%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Drug Research中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	PHARMACOLOGY & PHARMACY 药学	4区

Drug Research JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	ESCI	Q3	215 / 356	39.7
学科：PHARMACOLOGY & PHARMACY	ESCI	Q4	275 / 356	22.89

Drug Research历年数据统计

影响因子

中科院分区

Drug Research中国学者发文选摘

1、Advances in Janus Kinase Inhibitors for Vitiligo Treatmen
Author: Wang, Wanlin; Liao, Yue; Zhang, Ruizhi; Huang, Jijun; Liu, Jiamin; Shan, Xiaokang; Gao, Xiaojing; Bu, Jin; Tang, Yaping; Shen, Erxia

Journal: DRUG RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1055/a-2784-6722
2、Adverse Event Profile Differences Between Eliglustat and Miglustat: A Pharmacovigilance Study using the U.S. Food and Drug Administration Adverse Event Reporting Syste
Author: Gan, Ya; Liu, Jie; Xia, Chunyong

Journal: DRUG RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1055/a-2791-0972
3、A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drug
Author: Xu, Qiong; Cheng, Hongxia; Sun, Xu; Zhao, Jing; Chen, Yingying; Ji, Lingyu; Liang, Yan

Journal: DRUG RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1055/a-2575-1530
4、1α,25(OH)2D3 Regulates the TGF-β1/Samd Signaling Pathway Inhibition of Hepatic Stellate Cell Activatio
Author: Zhao, Yihan; Fan, Jianghao; Wang, Jia; Wan, Jie; Ma, Haiyan; Sha, Xiaoying; Wang, Hongli

Journal: DRUG RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1055/a-2463-5530
5、Fragment-Based Drug Discovery of KIF11 Inhibitors for Glioblastoma Treatment: Molecular Insights and Therapeutic Potentia
Author: Naseer, Qais Ahmad; Cao, Xuexian; Yimai, Deng; Khan, Muhammad Ajmal; Chen, Shengxia

Journal: DRUG RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1055/a-2512-9183